Logo Geneseeq
  • Services
    • Genomic Testing
      • Companion Diagnostic Test
      • Laboratory Developed Tests (LDT)
        • Solid Tumors
        • Hematologic Malignancies
        • Hereditary Cancers
        • Minimal Residual Disease
      • RUO Kit Solution
    • Research Services
      • Platforms
      • DNA Sequencing
      • RNA Sequencing
      • Other Services
  • Technology
    • Our Technology
    • Publications
  • Partnerships
  • About Us
    • What is Precision Oncology?
    • Our Company
    • Our Team
    • Certificates & Accreditation
  • News
  • Join Us
  • Contact Us
  • Ch|中文
  • Search

May 25, 2023

GENESEEQ TO SHOWCASE NEW FINDINGS AT ASCO 2023


by Geneseeq

May 16, 2023

Geneseeq published new research on the clinical use of circulating-free DNA fragmentomic in monitoring minimal residual disease for patients with non-small-cell lung cancer


by Geneseeq

October 18, 2022

Geneseeq study highlights ctDNA monitoring clinical value in colorectal cancer patients resistant to BRAF/EGFR-targeted therapy


by Geneseeq

August 31, 2021

Geneseeq Study Evaluates ctDNA MRD to Predict Response to Therapy and Assess Prognosis in Locally Advanced Rectal Cancer


by Geneseeq

May 26, 2021

Geneseeq Presenting Data at the American Society of Clinical Oncology Annual Meeting 2021


by Geneseeq

Logo Geneseeq

1-647-714-5020
1-800-362-0325
info.toronto@geneseeq.com

Quick Links
  • Services
  • Technology
  • News
  • About Us
Connect
  • Partnerships
  • Join us
  • Contact us
Privacy
  • Privacy Policy
  • Terms of Use
Headquarters

Main Office:
Suite 1802
393 University Avenue
Toronto, Ontario, M5G 1E6
Canada

© 2023 Geneseeq Technology Inc. | A Precision Oncology Company. All rights reserved

Privacy Preference Center

Privacy Preferences